Loading...
•
Sep 30, 2020
Syndax Q3 2020 Earnings Report
Syndax reported its financial results for the third quarter ended September 30, 2020.
Key Takeaways
Syndax Pharmaceuticals reported a net loss of $20.4 million, or $0.46 per share, for the third quarter of 2020. The company's research and development expenses increased to $14.4 million, and general and administrative expenses increased to $5.8 million. As of September 30, 2020, Syndax had $170.2 million in cash, cash equivalents and short-term investments.
Phase 1 data from AUGMENT-101 trial of SNDX-5613 and initiation of Phase 2 on track for early 2021.
Company provided update on axatilimab development plan in cGVHD following recent FDA interactions; expects to commence pivotal trial by year-end.
Data from Phase 1 trial of axatilimab in patients with cGVHD to be highlighted during oral presentation at ASH Annual Meeting in December.
Research and development expenses are expected to be $15 to $20 million, and total operating expenses are expected to be $20 to $25 million for the fourth quarter of 2020.
Forward Guidance
For the fourth quarter of 2020, research and development expenses are expected to be $15 to $20 million, and total operating expenses are expected to be $20 to $25 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...